Prediction Case File
YouTubeEvaluation Complete

Hims Gets CHEAP (-10% since Q2) while Nebius Gets Squeezed (NBIS Up 50% since Q2)—Which is my Fave?

2 extracted signals · 2 resolved · 0 still active

Beat The Denominator profile imageBeat The DenominatorIndependent analyst profile
Source published
15 Aug 2026, 01:02 UTC
Recorded by Tahlil Plus
18 Aug 2026, 16:18 UTC
Video preview for Hims Gets CHEAP (-10% since Q2) while Nebius Gets Squeezed (NBIS Up 50% since Q2)—Which is my Fave?
Source overview

AI-generated source summary

The analysis focuses on two stocks, HIMS and NBIS, highlighting a 'value disconnect'. HIMS has seen a roughly 10% drop after earnings, with its price action described as trading like a wild growth stock rather than a health company. Some argue this is due to aggressive price wars and promotions, leading to a reported gross profit margin drop. However, the analysis suggests that the marketing ROI has actually increased, and price drops are reflected in gross profit margins, not operating margins. The speaker believes that HIMS's growth might be underestimated, especially with potential upcoming catalysts like 'Peptides (BPC157 + TB500 by Oct 1?)'. The stock is currently trading around $28.15 and is considered bullish above $27.0, with a target of $31.0. NBIS, on the other hand, has experienced a significant price increase of approximately 50% in 5 days, indicating a battle between shorts and longs. This is compared to a similar situation with MU/NBIS last month. The speaker is cautiously optimistic about NBIS, suggesting it could reach a $1 trillion valuation by the early 2030s based on new pricing, but notes that the rapid price increase might be overdone, suggesting a potential short-term pullback or consolidation. The stock is currently trading around $277.68. The speaker views NBIS as a potential buy below $260.0, targeting $320.0. The analysis implies that both stocks have strong underlying potential that is not fully reflected in their current market valuation.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
2
Extracted from this source
Open
0
Still being tracked
Successful
1
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
50%
2 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    2 eligible signals linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. Source processing completed

    Source analysis and structured extraction completed.

  6. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  7. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

Beat The Denominator

Platform-wide history, separate from this source evaluation.

Reliability
56.8
Tracked signals
105
Historical success
47.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail